Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Flamm, Robert K.; Duncan, Leonard R; Hamed, Kamal; Smart, Jennifer I.; Mendes, Rodrigo E.; Pfaller, Michael A.

doi:10.1128/aac.02566-19

Cited by 15 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that ceftobiprole is generally β-lactamase stable and has a strong affinity for essential penicillin-binding proteins, including those responsible for β-lactam resistance in staphylococci and pneumococci [ 6 ]. Several studies have been reported on the spectrum and potency of ceftobiprole against Gram-positive and Gram-negative pathogens collected from Europe and surrounding countries in a variety of infection types [ 2 – 4 , 7 , 8 ]. In this present study, we expand upon those observations by reporting the activity of ceftobiprole and comparators against bacterial isolates obtained and tested during the 2016–2018 CHINET Antimicrobial Surveillance Network in China.…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)

et al. 2022

View full text Add to dashboard Cite

Background Ceftobiprole is a fifth-generation cephalosporin which has been reported to have broad antibacterial spectrum when tested against bacteria collected from other countries except China. This study evaluated the in vitro activity of ceftobiprole in comparison with other comparators against clinically significant isolates collected across from China. Results Susceptibility testing of ceftobiprole and comparators against 1163 clinically isolated Gram-positive and Gram-negative bacteria was performed with broth micro dilution method following the CLSI guidelines. All 110 S. aureus were susceptible to ceftobiprole with MIC50/90 of 1/2 mg/L for MRSA and 0.5/1 mg/L for MSSA. For Coagulase-negative staphylococci (CNS), MIC50/90 of ceftobiprole for MRCNS and MSCNS was 1/2 mg/L and 0.25/0.5 mg/L. Ceftobiprole demonstrated good potency against E. faecalis (MIC50/90 of 0.5/1 mg/L) but limited activity against E. faecium (MIC50/90 of > 32/ > 32 mg/L). Ceftobiprole demonstrated potent activity against all 39 β-hemolytic Streptococcus spp. with MIC50/90 ≤ 0.015/ ≤ 0.015–2 mg/L and 110 of PSSP with 98.2% susceptibility. Ceftobiprole inhibited all isolates of H. influenzae and M. catarrhalis at ≤ 1 mg/L. 91.8% and 98.2% of the ESBL-negative E. coli and K. pneumoniae were susceptible to ceftobiprole, but most of the ESBL-positive or carbapenem-resistant strains were also resistant to ceftobiprole. Ceftobiprole inhibited 84.2% of carbapenem-susceptible P. aeruginosa and 94.1% of carbapenem-susceptible A. baumannii at ≤ 8 mg/L, but only 52.6% of carbapenem-resistant P. aeruginosa and 5.3% of carbapenem-resistant A. baumannii. Conclusion Ceftobiprole demonstrated good in vitro activity against a broad range of clinically relevant contemporary Gram-positive and Gram-negative bacterial isolates.

show abstract

Section: Introductionmentioning

confidence: 99%

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As one of the limited new effective antibiotics approved for treating infection caused by resistant Gram-positive and Gram-negative bacteria, ceftobiprole has been proved by several studies in different medical centers around the world [7,10,11]. However, this literature data are absent in China.…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial activity of ceftobiprole and comparator agents when tested against Gram-positive and -negative organisms collected across China (2016-2018)

yin

Shi

Yang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Ceftobiprole is a fifth-generation cephalosporin which has been reported on the antibacterial spectrum when against bacteria collected from other countries except China. This study evaluated the in vitro activity of ceftobiprole in comparison with other comparators against clinically significant isolates collected across from China. Results: Susceptibility testing of ceftobiprole and comparators against 1163 clinically isolated Gram-positive and Gram-negative bacteria was performed with broth micro dilution method following the CLSI guidelines. All 110 S. aureus were susceptible to ceftobiprole with MIC50/90 of 1/2 mg/L for MRSA and 0.5/1 mg/L for MSSA. For Coagulase-negative staphylococci (CNS), MIC50/90 of ceftobiprole for MRCNS and MSCNS was 1/2 mg/L and 0.25/0.5 mg/L. Ceftobiprole demonstrated good potency against E. faecalis (MIC50/90 of 0.5/1 mg/L) but bad against E. faecium (MIC50/90 of >32/>32 mg/L). Ceftobiprole demonstrated potent activity against all 39 β-hemolytic Streptococcus with MIC50/90 ≤0.015/≤0.015-2 mg/L and 110 of PSSP with 98.2% susceptibility. Ceftobiprole inhibited all isolates of H. influenzae and M. catarrhalis at ≤ 1 mg/L. 91.8% and 98.2% of the ESBL-negative E. coli and K. pneumoniae were susceptible to ceftobiprole, but most of the ESBL-positive or carbapenem-resistant strains were also resistant to ceftobiprole. Ceftobiprole inhibited 84.2% of carbapenem-susceptible P. aeruginosa and 94.1% of carbapenem-susceptible A. baumannii at ≤8 mg/L, but only 52.6% of carbapenem-resistant P. aeruginosa and 5.3% of carbapenem-resistant A. baumannii. Conclusion: Ceftobiprole was active in vitro against a broad range of clinically relevant contemporary Gram-positive and Gram-negative bacterial isolates.

show abstract

“…In vitro studies have shown that both ceftaroline and ceftobiprole exhibit potent in vitro activity against commonly encountered gram-positive bacteria, including MRSA, penicillin-resistant Streptococcus pneumoniae, Enterococcus faecalis, and gram-negative pathogens such as Citrobacter spp., Escherichia coli , Enterobacter spp., Klebsiella spp., and Serratia spp. [ 13 , 14 , 15 , 16 ]. Therefore, these two anti-MRSA cephalosporins could be recommended as therapeutic options for ABSSSIs.…”

Section: Introductionmentioning

confidence: 99%

Anti-MRSA Cephalosporin versus Vancomycin-Based Treatment for Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Chen

Lai

et al. 2021

Antibiotics

View full text Add to dashboard Cite

This systematic review and meta-analysis of randomized controlled trials (RCTs) compared the clinical efficacy and safety of anti-MRSA cephalosporin and vancomycin-based treatment in treating acute bacterial skin and skin structure infections (ABSSSIs). PubMed, Embase, Cochrane Central Register of Controlled Trials, Turning Research into Practice, and ClinicalTrials.gov databases were searched for relevant articles from inception to 15 June 2020. RCTs comparing the clinical efficacy and safety of anti-MRSA cephalosporin with those of vancomycin-based regimens in treating adult patients with ABSSSIs were included. The primary and secondary outcomes were clinical response at the test-of-cure assessments and risk of adverse events (AEs), respectively. Eight RCTs were enrolled. The clinical response rate was not significantly different between anti-MRSA cephalosporin and vancomycin-based treatments (odds ratio [OR], 1.05; 95% CI, 0.90–1.23; I2 = 0%). Except for major cutaneous abscesses in which anti-MRSA cephalosporin-based treatment was associated with a lower clinical response rate than vancomycin-based treatment (OR, 0.62; 95% CI, 0.40–0.97; I2 = 0%), other subgroup analyses according to the type of cephalosporin (ceftaroline or ceftobiprole), type of infection, and different pathogens did not show significant differences in clinical response. Anti-MRSA cephalosporin-based treatment was only associated with a higher risk of nausea than vancomycin-based treatment (OR, 1.41; 95% CI, 1.07–1.85; I2 = 0%). In treating ABSSSIs, the clinical efficacy of anti-MRSA cephalosporin is comparable to that of vancomycin-based treatment, except in major cutaneous abscesses. In addition to nausea, anti-MRSA cephalosporin was as tolerable as vancomycin-based treatment.

show abstract

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Cited by 15 publications

References 28 publications

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)

Antimicrobial activity of ceftobiprole and comparator agents when tested against Gram-positive and -negative organisms collected across China (2016-2018)

Anti-MRSA Cephalosporin versus Vancomycin-Based Treatment for Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About